Loading news...
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Becker Capital Management Inc. decreased its position in Pfizer Inc. (NYSE: PFE) by 14.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 325,863 shares of the biopharmaceutical company's stock after selling 54,103 shares during the quarter. Becker Capital
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but it has a rich pipeline of drugs in development.
Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U.S. Food and Drug Administration's vaccine department.
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.
Regencell Bioscience's outrageous performance in the past year is baffling. Despite the stock's sharp rise, there is little to look forward to for the drugmaker.
March's Large Cap Value (GASV) screen highlights 14 fair-priced, 'safer' dividend stocks, including Hafnia Ltd, IRSA Inversiones, and Weibo Corp, as actionable buys. Top ten GASV stocks are projected to deliver an average 33.21% net gain by March 2027, with risk/volatility slightly below the market average. Analyst targets indicate the five lowest-priced, highest-yield GASV stocks could outperform, with Hafnia Ltd showing a potential 42.88% gain.
Eli Lilly is the current leader in the GLP-1 weight-loss drug space. Investors have placed a high valuation on Lilly's stock.
APG Asset Management N.V. lowered its position in shares of Pfizer Inc. (NYSE: PFE) by 22.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,501,524 shares of the biopharmaceutical company's stock after selling 1,033,141 shares during the period. APG Asset Management N.V.
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative.
Dana Investment Advisors Inc. lessened its stake in shares of Pfizer Inc. (NYSE: PFE) by 35.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,811 shares of the biopharmaceutical company's stock after selling 36,261 shares during the quarter. Dana Investment Advisors
Andra AP fonden increased its holdings in shares of Pfizer Inc. (NYSE: PFE) by 22.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 996,700 shares of the biopharmaceutical company's stock after acquiring an additional 180,600 shares during the quarter. Andra AP fonden's
Shifting from higher-risk assets to consistent income sources is a natural progression for retirees.
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October, 2024. Steven Wieting, strategist at Citi Wealth, told Barron's a growing dividend is a tangible-benefit for shareholders and a hallmark of companies with strong balance-sheets. “Nobody can fake a dividend," he-said.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421). BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted.
Pfizer is dealing with headwinds right now, but they aren't unusual headwinds in the pharmaceutical sector. The company is taking aggressive actions to get back on track and recently stated it plans to support its dividend.
In the latest China pharmaceutical industry collaboration pact with a global drug leader, Hangzhou Sciwind Biosciences said today it had reached an agreement with Pfizer China to team up on the commercialization of a new-generation weight management and diabetes treatment, in a deal worth up to $495 million for the Chinese company.